Each patient's population of tumor cells mutates over
time, which may result in resistance to traditional
anticancer therapies1
When a tumor cell is killed, additional antigens are released, stimulating activation of new populations of
T cells and B cells that recognize tumor antigens1,2,4,5
This can result in an expanding cascade of immune cells that is able to recognize cancer cells bearing a variety of tumor antigens as the tumor mutates over time3-6
Learn more by watching Immunotherapy Is Designed to Support Immune System Adaptability (2:43)